SCHEMBL23016142

SCHEMBL23016142

c1cnc2c(c1)ccc1ccc(-c3ccc4cc(-c5ccc6cc(-c7ccc8nc(-c9ccc%10ccc%11cccnc%11c%10n9)ccc8c7)ccc6n5)ccc4c3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
POLB P06746 1/20 0.53
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
CCR1 P32246 2/20 0.47
CCR5 P51681 2/20 0.47
CCR8 P51685 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
NFKB1 P19838 2/20 0.47
GMNN O75496 1/20 0.47
TP53 P04637 1/20 0.47
HSP90AA1 P07900 1/20 0.47
MMP2 P08253 1/20 0.47
MAPT P10636 1/20 0.47
MMP9 P14780 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23016257 0.97 NPC1 (0.50) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL23016156 0.96 NPC1 (0.49) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL23016176 0.96 POLB (0.60) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL23016359 0.96 NPC1 (0.51) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL23016315 0.95 NPC1 (0.54) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL18943900 0.95 NPC1 (0.58) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL23016140 0.94 NPC1 (0.50) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL23016323 0.94 NPC1 (0.50) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL24475752 0.93 NPC1 (0.46) NPC1RAB9APOLBKDM4ESMN1; SMN2
SCHEMBL23016195 0.93 NPC1 (0.49) NPC1RAB9APOLBKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10930857-B2 Heterocyclic compound and organic light emitting device using same LT MATERIALS CO., LTD. (KR) 2021-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10930857-B2 Heterocyclic compound and organic light emitting device using same CRY1, CRY2, CYBA NPC1 4299/4885RAB9A 3913/4885POLB 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.